Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback